Evotec Releases Corporate Update

Evotec Releases Corporate Update

HAMBURG, Germany, March 18, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) today announced that Dr Werner Lanthaler, Chief Executive Officer of
Evotec, will resume his role as Chief Executive Officer of the Company with
immediate effect after a period of leave due to health reasons.

Dr Flemming Ornskov, Chairman of the Supervisory Board of Evotec AG,
commented: "The board is delighted to welcome back Dr Lanthaler to resume his
leadership of Evotec and to continue to drive the growth of the Company
through Action Plan 2016. The board would also like to thank the Management
Team of Colin Bond, Dr Cord Dohrmann and Dr Mario Polywka for managing the
company in Dr Lanthaler's absence."


Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
and with Roche in the field of Alzheimer's disease. For additional information
please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen, Head of Corporate Communications
Press spacebar to pause and continue. Press esc to stop.